Kyung Nam Pharm Co Ltd banner
K

Kyung Nam Pharm Co Ltd
KOSDAQ:053950

Watchlist Manager
Kyung Nam Pharm Co Ltd
KOSDAQ:053950
Watchlist
Price: 642 KRW -2.58% Market Closed
Market Cap: ₩50.2B

P/OCF

-29.8
Current
262%
More Expensive
vs 3-y average of -8.2

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
-29.8
=
Market Cap
₩50.2B
/
Operating Cash Flow
₩-1.7B

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
-29.8
=
Market Cap
₩50.2B
/
Operating Cash Flow
₩-1.7B

Valuation Scenarios

Kyung Nam Pharm Co Ltd is trading above its industry average

If P/OCF returns to its Industry Average (15.3), the stock would be worth ₩-329.65 (151% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-151%
Maximum Upside
No Upside Scenarios
Average Downside
141%
Scenario P/OCF Value Implied Price Upside/Downside
Current Multiple -29.8 ₩642
0%
Industry Average 15.3 ₩-329.65
-151%
Country Average 9 ₩-193.4
-130%

Forward P/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward P/OCF

Peer Comparison

All Multiples
P/OCF
P/E
All Countries
Close
Market Cap P/OCF P/E
KR
Kyung Nam Pharm Co Ltd
KOSDAQ:053950
50.2B KRW -29.8 -5.6
US
Eli Lilly and Co
NYSE:LLY
835.2B USD 49.7 40.5
US
Johnson & Johnson
NYSE:JNJ
547.8B USD 22.3 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 13.7 20.1
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 19.8 28.2
CH
Novartis AG
SIX:NOVN
218.2B CHF 14.3 19.6
US
Merck & Co Inc
NYSE:MRK
276.9B USD 16.8 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 907.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 9.9 11.5
US
Pfizer Inc
NYSE:PFE
153.5B USD 13.1 19.8
US
Bristol-Myers Squibb Co
NYSE:BMY
118.2B USD 8.3 16.8
P/E Multiple
Earnings Growth PEG
KR
K
Kyung Nam Pharm Co Ltd
KOSDAQ:053950
Average P/E: 22
Negative Multiple: -5.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.5
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28.2
25%
1.1
CH
Novartis AG
SIX:NOVN
19.6
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.8
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1

Market Distribution

Lower than 100% of companies in Korea
Percentile
0th
Based on 1 012 companies
0th percentile
-29.8
Low
0.2 — 4.2
Typical Range
4.2 — 16.6
High
16.6 —
Distribution Statistics
Korea
Min 0.2
30th Percentile 4.2
Median 9
70th Percentile 16.6
Max 2 215 132.4

Kyung Nam Pharm Co Ltd
Glance View

Market Cap
50.2B KRW
Industry
Pharmaceuticals

Kyungnam Pharm Co., Ltd. manufactures pharmaceutical products. The company is headquartered in Uiryeong-Gun, Gyeongsangnam-Do. The company went IPO on 2001-11-06. The firm's product portfolio consists of vitamin products, placenta products, health food products and general pharmaceuticals. The firm provides vitamin products under the brand name LEMONA. The company supplies health food products such as lactobacillus products through convenient stores and marts. The placenta products include human placenta related injections and drinks. The general pharmaceuticals include athlete foot therapeutic agents, inflammatory drugs, cold remedies, multi-nutrients and others.

Intrinsic Value
787.64 KRW
Undervaluation 18%
Intrinsic Value
Price ₩642
K
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett